{
  "compound": "Cannabidiol (Epidiolex)",
  "condition": "EPILEPSY",
  "effect_size": "Large (25.6% difference)",
  "study_type": "RCT",
  "source": "NORML:EPILEPSY_RCT_001",
  "participants": "120 children and young adults with Dravet syndrome",
  "year": 2017,
  "notes": "Epidiolex (CBD) for Dravet Syndrome: Pivotal Phase 3 Trial",
  "confidence": "medium",
  "abstract": "CBD: 38.9% reduction vs Placebo: 13.3% (p=0.01); 5% seizure-free; 43% achieved \u226550% reduction"
}